Scinovex
articleTop 1% cited

Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome

The American Journal of Gastroenterology · 2006 · Vol. 101(7) · pp. 1581–1590
Peter J. WhorwellL. A. AltringerJorge G. MorelYvonne BondDuane CharbonneauLiam O’MahonyBarry KielyFergus ShanahanEamonn M.M. Quigley

Abstract

B. infantis 35624 is a probiotic that specifically relieves many of the symptoms of IBS. At a dosage level of 1 x 10(8) cfu, it can be delivered by a capsule making it stable, convenient to administer, and amenable to widespread use. The lack of benefits observed with the other dosage levels of the probiotic highlight the need for clinical data in the final dosage form and dose of probiotic before these products should be used in practice.

Gastrointestinal motility and disordersInfant Health and DevelopmentProbiotics and Fermented FoodsIrritable bowel syndromeMedicineBloatingProbioticAbdominal painInternal medicinePlaceboBifidobacteriumGastroenterologyRandomized controlled trial

MeSH terms

AdolescentAdultAgedBifidobacteriumCapsulesDouble-Blind MethodFemaleUnited KingdomHumansMiddle AgedLinear ModelsTreatment OutcomeProbioticsIrritable Bowel Syndrome
Citations
788
FWCI
24.59
field-weighted impact
References
39
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.